Additional Commentary:

Is hydroxyurea considered leukemogenic?

Additional Commentary:

Is there cross-resistance between ruxolitinib and other JAK2 inhibitors?

Additional Faculty Comments:

• Cross-resistance between Rux and other JAK2 inhibitors?
• Is hydroxyurea considered leukemogenic?
• How common is the occurrence of hydroxyurea-related leg ulcers?
• Role of iron chelation for pts with MF and frequent transfusions?

OVERVIEW OF ACTIVITY

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses and other practitioners involved in the management of myelofibrosis.

Patterns of Care Data Regarding Ruxolitinib Use in Patients without JAK2 Mutations

Allotransplant in patients with MF?

In what situations, if any, do you recommend allotransplant to patients with MF?

Splenectomy in patients with MF?

Presently, how often do you recommend splenectomy to patients with MF?

Other diseases most commonly confused with MF?

Based on your clinical experience, which of the following disease states is most often confused with a diagnosis of myelofibrosis (MF)?

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses and other practitioners involved in the management of myelofibrosis.